AI Drug Discovery Company
Appears in 4 stories
Advancing AI-designed drug candidates toward clinical trials
Google released an AI system in February 2025 that proposes original hypotheses and refines them through internal debate among six specialized AI agents. The system reproduced a decade-long Imperial College London study on how antibiotic-resistance genes spread between bacterial species in 48 hours, without accessing their unpublished findings.
Updated May 30
Released proprietary IsoDDE model in February 2026; partnerships with major pharmaceutical companies
Determining the three-dimensional shape of a protein used to take a graduate student an entire career. Google DeepMind released AlphaFold 4 in March 2026, extending progress from the original AlphaFold's 2018 win, with the system predicting multi-protein structures in minutes instead of hours or days.
Raised $2.1 billion Series B in May 2026; expects first AI-designed clinical candidates in human trials by end-2026
In January 2026, researchers at Tsinghua University published DrugCLIP in Science—a system that screened 500 million drug compounds against 10,000 human proteins in under 24 hours using eight GPUs. That is 10 million times faster than conventional molecular docking. The results are publicly available in GenomeScreenDB, giving any lab access to screening data across roughly half the human genome.
Updated May 26
First clinical trials expected late 2026
Science magazine named large language models doing frontier science a runner-up breakthrough of 2025. Within weeks, the prediction became reality: OpenAI's GPT-5.2 solved previously unsolved Erdős mathematics problems in 15 minutes, achieving 40% accuracy on expert-level mathematics that stumped earlier systems.
Updated May 19
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
